Moderna, Inc. Common Stock vs. Vericel Corporation
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| MRNA | VCEL | |
|---|---|---|
| Market Cap | $59.43 billion | $2.07 billion |
| Revenue (TTM) | $2.23 billion | — |
| Net Income (TTM) | $-3,151,000,000 | — |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| MRNA | VCEL | |
|---|---|---|
| Price / Book | 8.79 | — |
| Price / Sales | 26.68 | — |
MRNA and VCEL split the valuation factors evenly.
Profitability
| MRNA | VCEL | |
|---|---|---|
| Net Margin | -141.43% | — |
| Return on Equity | -46.61% | — |
MRNA and VCEL split the profitability factors evenly.
Risk & Sentiment
| MRNA | VCEL | |
|---|---|---|
| Short Interest | 0.01% | 2.79% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, VCEL overview, VCEL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.